Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials-Reference-Cited by-同舟云学术

Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials

Published:2023-07 Issue:7 Volume:24 Page:783-797
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Vale Claire L,Fisher David J,Godolphin Peter J,Rydzewska Larysa H,Boher Jean-Marie,Burdett Sarah,Chen Yu-Hui,Clarke Noel W,Fizazi Karim,Gravis Gwenaelle,James Nicholas D,Liu Glenn,Matheson David,Murphy Laura,Oldroyd Robert E,Parmar Mahesh K B,Rogozinska Ewelina,Sfumato Patrick,Sweeney Christopher J,Sydes Matthew R,Tombal Bertrand,White Ian R,Tierney Jayne F

Publisher

Elsevier BV

Subject

Oncology

Reference50 articles.

1. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data;Vale;Lancet Oncol,2016

2. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial;Kyriakopoulos;J Clin Oncol,2018

3. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer;Sweeney;N Engl J Med,2015

4. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial;Gravis;Lancet Oncol,2013

5. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial;Gravis;Eur Urol,2016

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrative Chinese-Western medicine strategy to overcome docetaxel resistance in prostate cancer;Journal of Ethnopharmacology;2024-09

2. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II—2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer;European Urology;2024-08

3. Outcomes of First-Line Abiraterone Acetate or Enzalutamide for Older Adults With Metastatic Castration-Resistant Prostate Cancer According to Use of Upfront Docetaxel for Metastatic Castration-Sensitive Prostate Cancer in an International Multicenter Registry: A SPARTACUSS—Meet-URO 26 Study;Clinical Genitourinary Cancer;2024-08

4. Front-Line Therapeutic Strategy in Metastatic Hormone Sensitive Prostate Cancer: An Updated Therapeutic Algorithm;Clinical Genitourinary Cancer;2024-08

5. Systemic Treatments for Metastatic Prostate Cancer in 2024;European Urology Focus;2024-08